On the Radar: November's biotech stocks to watch

[SOURCE: Fierce Biotech] This month three Canaccord Adams analysts--Adam Cutler, George Farmer and Ritu Baral (bios and photos)--weigh in on five developers that are facing pivotal events. A timely regulatory approval would mean a lot for one of these companies, another is pushing a new cancer therapy into crucial late-stage trials and a third is fishing for a potential partnership that could make a big difference as it advances three programs in the clinic. A well-timed NDA filing could set the stage for another pact while our fifth company faces a near-term decision from the FDA and some big decisions on a possible partner. Featured in this issue of On the Radar are Cadence Pharmaceuticals, Micromet, Momenta Pharmaceuticals, Pharmasset, and Protalix BioTherapeutics.

Download Von D Stella Sesh Guest Mix Here


1) Mr Lager ft Alyz be - Tell me (Von D remix) (dub)
2) Von D - Chacha's Leggings (Forthcoming Subbalicious)
3) Von D & Dj Madd - Cold Night (dub)
4) Von D Ft Phephe - Show me (Subfreq)
5) Riskotheque - Badbwoy (Dub)
6) Smokah - The Same (Dub)
7) Von D ft Warrior Queen - Moon eclipse (forthcoming Black Acre)
8)Von D & Riskotheque - Like a Bird (forthcoming disgured Dubs)
9) Von D Ft Phephe - Sunlight (forthcoming Subbalicious)
10) Von D & Nivo O - The lair (dub)
11) Von D - Pink (dub)
12) Jay Kenzo - Hoods Up (dub)
13) Von D - Berlin call (forthcoming Argon)
14) Matt U - Watchin U (dub)
15) Von D Ft Alyz be - I can't say no (dub)

Lower End Spasm] Sinogrime is a sub-genre that barely ever existed, a momentary glitch in the supposedly predictable sonic geography of London dance music. Around 2002-3, with garage crumbling and the cement still drying on grime as a genre, a few producers in E3 suddenly lurched further east than they ever had before.

No tracklist I’m afraid – “all the tracks are Jammer/Wiley/Wookie/Wonder/Geeneus, but there were no track names on the Jammer whites”.

[Source: PRNewswire] - The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain. Corus CAD is a new genomic test launched in select U.S. markets, and the Heart & Vascular Center of Arizona is among the first institutions in the country to offer this first-of-its-kind gene expression test to patients with possible cardiovascular disease.

For more information: New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona